Health News

Pharmasset, Inc. announced today that dosing has begun in a Phase 2b study of PSI-7977, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 200mg QD and 400mg QD in combination with pegylated interferon alfa 2a and ribavirin, the current standard of care (SOC) in patients with HCV genotype 1 who have not been treated previously.

Read more

Filed under: Pharmacy News
Tags: Hepatitis, Pharmacy

Related posts

• ZymoGenetics completes enrollment in Phase 2b PEG-IFN lambda clinical trial (0)
  ZymoGenetics, Inc. today announced enrollment has been completed in the Phase 2b clinical trial with PEG-Interferon lambda and ribavirin in chronic hepatitis C virus (HCV) infection. Read more [tags] Pharmacy News [/tags]
  
  
• ZymoGenetics commences Phase 2B study of PEG-Interferon lambda in hepatitis C (0)
  ZymoGenetics, Inc. today announced the initiation of the second part of a Phase 2 clinical trial with PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection. ZymoGenetics is developing the investigational compound PEG-Interferon lambda in collaboration with Bristol-Myers Squibb Company. Read more [tags] Pharmacy News [/tags]
  
  
• Weight-based taribavirin reduces anemia, increases sustained virologic response (0)
  Researchers at Cedars-Sinai Medical Center and 50 other centers found that weight-based dosing of taribavirin reduces rates of anemia while increasing sustained virologic response (SVR) in patients with chronic hepatitis C (HCV). Full details of this study are available in the October issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American [...]
  
  
• VGX International, Inovio partner to co-develop SynCon vaccines for hepatitis B and C infections (0)
  Inovio Pharmaceuticals, Inc., a leader in the development of synthetic vaccines against cancers and infectious diseases, announced today that it has entered into a product development collaboration agreement with its affiliate, VGX International Inc., to co-develop Inovio's SynCon therapeutic vaccines for hepatitis B and C infections. Read more [tags] Pharmacy News [/tags]
  
  
• Vertex to present telaprevir and VX-222 study results against hepatitis C at EASL annual meeting (0)
  Vertex Pharmaceuticals Incorporated announced today that 15 abstracts on the company's medicines in development for hepatitis C, including its protease inhibitor, telaprevir, and polymerase inhibitor, VX-222, were accepted for presentation at the 46th Annual Meeting of the European Association for the Study of the Liver in Berlin, Germany, March 30 to April 3, 2011. Read more [tags] [...]